Evidence map›Paper›PMID 39996769›Full record

ArticleCells2025

Selected Elements of the Tumor Microenvironment (MMP-2, MMP-7, TIMP-2, CXCL-9, CXCL-10) in the Serum of Pediatric Patients with Acute Lymphoblastic Leukemia.

Aleksandra Kaczorowska, Natalia Miękus-Purwin, Anna Owczarzak, Anna Gabrych, Małgorzata Wojciechowska, Ninela Irga-Jaworska, Sylwia Małgorzewicz, Małgorzata Rąpała, Joanna Stefanowicz

Abstract read
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aleksandra KaczorowskaDepartment of Pediatrics, Hematology and Oncology, University Clinical Center of Gdansk, Debinki 7, 80-211 Gdańsk, Poland.
Natalia Miękus-PurwinIndependent Researcher, 81-553 Gdynia, Poland.ORCID 0000-0002-9605-3259
Anna OwczarzakDivision of Clinical Nutrition and Dietetics, Faculty of Health Sciences with the Institute of Maritime and Tropical Medicine, 7 Dębinki, 80-211 Gdańsk, Poland.
Anna GabrychDepartment of Pediatrics, Hematology and Oncology, University Clinical Center of Gdansk, Debinki 7, 80-211 Gdańsk, Poland.
Małgorzata WojciechowskaDepartment of Pediatrics, Hematology and Oncology, University Clinical Center of Gdansk, Debinki 7, 80-211 Gdańsk, Poland.
Ninela Irga-JaworskaDepartment of Pediatrics, Hematology and Oncology, University Clinical Center of Gdansk, Debinki 7, 80-211 Gdańsk, Poland.
Sylwia MałgorzewiczDivision of Clinical Nutrition and Dietetics, Faculty of Health Sciences with the Institute of Maritime and Tropical Medicine, 7 Dębinki, 80-211 Gdańsk, Poland.ORCID 0000-0001-8773-9649
Małgorzata RąpałaDepartment of Pediatric Surgery, Marciniak Hospital, 2 Gen. Augusta Emila Fieldorfa, 54-049 Wroclaw, Poland.ORCID 0000-0002-2789-5911
Joanna StefanowiczDepartment of Pediatrics, Hematology and Oncology, University Clinical Center of Gdansk, Debinki 7, 80-211 Gdańsk, Poland.ORCID 0000-0001-8014-4263

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, researchers have been paying special attention to the tumor microenvironment (TME). One of the most important factors contributing to the development and progression of cancer is the destruction of elements of the extracellular matrix (ECM). The most important substances involved in regulating the extracellular matrix degradation process are extracellular matrix metalloproteinases (MMPs) and their inhibitors (TIMPs). In the process of cancer cell migration, chemokines secreted by target tissues, as well as the profile of chemokine receptors presented on cancer cells, play a key role. In the presented work, five components of the TME were selected: MMP-2, MMP-7, TIMP-2, CXCL-9, and CXCL-10. In the years 2018-2021, peripheral blood samples were collected before the start of treatment and then on day 33 of intensive treatment from 31 patients diagnosed with ALL. The results indicate that the levels of MMP-2, MMP-7, and TIMP-2 did not statistically significantly change before and during treatment of ALL patients. The decrease in CXCL-9 and CXCL-10 levels in the patients' serum on the 33rd day of therapy turned out to be statistically significant. Our study indicates that serum is also a valuable material for the evaluation of these substances. Conclusions: CXCL-9 and CXCL-10 could be used as one of markers for monitoring the response to treatment and a potential marker of ALL recurrence in pediatric patients. The role of MMP-2, MMP-7, and TIMP-2 in the assessment of response to therapy in children with ALL has not been confirmed.

Indexed as

Chemokine CXCL10Chemokine CXCL9Matrix Metalloproteinase 2Matrix Metalloproteinase 7Precursor Cell Lymphoblastic Leukemia-LymphomaTissue Inhibitor of Metalloproteinase-2Tumor MicroenvironmentAdolescentChildChild, PreschoolFemaleHumansInfantMaleChemokine CXCL10Chemokine CXCL9CXCL10 protein, humanCXCL9 protein, humanMatrix Metalloproteinase 2Matrix Metalloproteinase 7MMP2 protein, humanMMP7 protein, humanTIMP2 protein, humanTissue Inhibitor of Metalloproteinase-2chemokinescytokinesleukemiametalloproteinasespediatric cancertissue inhibitors of metalloproteinasestumor microenvironment

Identifiers

PMID39996769
PMCPMC11854448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.